The Canada hepatitis therapeutics market size stood at around USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of xx% during the forecast period.
The hepatitis market especially that of hepatitis B is having great demand in Canada. In 2018, the overall reported rate of hepatitis C infection in Canada was 33.6 cases per 100,000 people. The Public Agency of Canada estimated that 317,100 people in Canada ever had hepatitis C in 2017. Of these, an estimated 194,500 people were living with chronic hepatitis C. In 2017, a total of 4,905 cases of HBV infection were reported in Canada.
The increasing prevalence of hepatitis cases in Canada along with the promising pipeline of hepatitis drugs and the increasing government attention and initiatives encouraging the patients in the adoption of hepatitis drugs in Canada. The introduction of generic versions of HCV drugs has changed the market dynamics across Canada. With more people being able to afford the generic versions, the usage rates of its drugs are expected to grow rapidly over the next few years and as the accessibility of these drugs is a major issue among the low-income group, the generic cases are a saviour when it comes to the treatment of hepatitis in Canada.
Infectious causes are further subdivided into viral, parasitic, and bacterial among which viral is the most common one.
Autoimmune causes are further subdivided into Alcoholic, Toxic, and drug-induced as well as Non- alcoholic fatty liver disease.
It is a chronic disease caused by an abnormal immune response against liver cells.
Genetic causes of hepatitis include alpha-1-antitrypsin deficiency, hemochromatosis, and Wilson’s disease and are hereditary.
It is characterized by reduced blood flow to the liver because of shocks, vascular inefficiency, or heart failure.